About Us

In business 10 years, Aberjona Laboratories Inc. a Massachusetts based corporation, is a unique chemical products provider and chemistry-based drug discovery service company dedicated to providing drug discovery services, solutions as well as products to biotechnology, pharmaceutical and genomics companies. Our credibility and proven track record has made us the best organic and medicinal chemistry team around. We have the ability of designing from concept to accomplishing the synthesis of drug candidates at high-speed and short turnaround time from 2 days to 2 weeks. Our extensive experience in organic synthesis allows us to offer high quality services and products in any areas. Two co-invented drug candidates are in the clinical trials. Three patents have been filed with Boston Biomedical Inc. Six scientific papers have been published with our collaborators at Harvard Medical School. Aberjona has a wholly owned state-of-the-art facility in Woburn, 9 miles (14 km) north of Boston, MA.

  1. (Collaborative work with MGH, Harvard Medical School) “Cytoprotective effects of hydrogen sulfide-releasing N-methyl-D-aspartate receptorantagonists are mediated by intracellular sulfane sulfur." MedChemComm, 2014, 1577-1583.
  2. (Collaborative work with BWH, Harvard Medical School) “Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors” Bioorg. Med. Chem. Lett. 2012, 2015-2019.
  3. (Collaborative work with MGH, Harvard Medical School) “In vivo and in vitro pharmacological studies of methoxycarbonyl-carboetomidate” Anesthesia & Analgesia, 2012, 297-304.
  4. (Collaborative work with BWH, Harvard Medical School) “Structure-activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors” Bioorg. Med. Chem. Lett. 2010, 3491-3494.
  1. (Collaborative work with BWH, Harvard Medical School) “Structure activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors” Bioorg. Med. Chem. Lett. 2008, 18, 4388 – 4392.
  2. (Collaborative work with Boston Biomedical Inc.) “Preparation of inhibitors of kinases and cancer stem cells” US 20140275033 A1, 2014.
  3. (Collaborative work with Boston Biomedical Inc.) “Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases” WO 2009033033, 2009.
  4. (Collaborative work with Boston Biomedical Inc.) “A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors.” WO 2009036099 A1, 2009.

 

  • One scientific paper recognized as the “Most-Cited and Most-Accessed Article of 2006” from J. Comb. Chem., the American Chemical Society.
  • One scientific paper received “Tetrahedron Letters 2005 – 2008 Most-Cited Article Award” from Elsevier.